Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
暂无分享,去创建一个
Elaine Coustan-Smith | Dario Campana | Ching-Hon Pui | James M Boyett | F. Behm | S. Raimondi | D. Campana | C. Pui | E. Coustan-Smith | J. Rubnitz | M. Hancock | G. Rivera | Susana C Raimondi | Jeffrey E Rubnitz | J. Boyett | J. Sandlund | Michael L Hancock | Frederick G Behm | Gaston K Rivera | Joaquin Sanchez | J Torrey Sandlund | Joaquín Sánchez | G. K. Rivera | Dario Campana | S. C. Raimondi
[1] E. Thiel,et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. , 1995, Leukemia.
[2] S. Misawa,et al. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. , 1995, Leukemia.
[3] F. Behm,et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. , 1996, Blood.
[4] M. Potter,et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. , 1994, Blood.
[5] A. Morley,et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.
[6] N. Cross,et al. Quantitative PCR techniques and applications. , 1995, British journal of haematology.
[7] C. Pui. Medical progress : childhood leukemias , 1995 .
[8] F. Behm,et al. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. , 1993, Leukemia.
[9] C. E. van der Schoot,et al. Triple immunofluorescence staining for prediction of relapse in childhood precursor B acute lymphoblastic leukaemia , 1996, British journal of haematology.
[10] M. Koehler,et al. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. , 1991, Blood.
[11] D. Johnston,et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. , 1997, The New England journal of medicine.
[12] D. Campana,et al. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.
[13] F. Behm,et al. Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. , 1997, Blood.
[14] B. Lange,et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Campana,et al. The immunologic detection of minimal residual disease in acute leukemia. , 1990, Blood.
[16] G. Basso,et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. , 1992, Leukemia.
[17] H. Cavé,et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. , 1994, Blood.
[18] J. V. van Dongen,et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. , 1994, Blood.
[19] J. Silber,et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Relling,et al. Risk-Adapted Treatment for Acute Lymphoblastic Leukemia: Findings from St. Jude Children’s Research Hospital , 1997 .
[21] G. Kitchingman. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. , 1994, Leukemia.
[22] C. E. van der Schoot,et al. Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease. , 1995, Blood.
[23] A. Órfão,et al. Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry. , 1994, Leukemia & lymphoma.
[24] P. Martiat,et al. A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse , 1997, British journal of haematology.
[25] I. Bernstein,et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. , 1996, Blood.
[26] P. Martiat,et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. , 1993, Blood.
[27] M. Relling,et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. , 1997, The New England journal of medicine.